Valsartan

Hazard statements (CLP)

H336, H361d

Code

Statements

H336

May cause drowsiness or dizziness

SECTION 2: Hazards identification

Labelling according Regulation (EC) No 1272/2008 as amended by GB-CLP Classification of the substance or mixture

Signal word

Warning Warning

Hazard statements

H336 May cause drowsiness or dizziness. H361d Suspected of damaging the unborn child. Reduced Labeling (<= 125 ml) H361d Suspected of damaging the unborn child.

Precautionary statements

P201 Obtain special instructions before use. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P201 Obtain special instructions before use. P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Supplemental label elements

none none

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

ECOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

TOXICOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

2.1 Classification of the substance or mixture

Classification according to Regulation (EC) No 1272/2008 as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567 Reproductive toxicity, (Category H361d: Suspected of damaging the unborn 2) child. Specific target organ toxicity - H336: May cause drowsiness or dizziness. single exposure, (Category 3), Central nervous system